Last update 08 May 2025

Vernalis Group Plc

Dissolved
| Private Company|United Kingdom

Overview

Related

5
Drugs associated with Vernalis Group Plc
CEB-1342
Target-
Mechanism-
Active Org.-
Originator Org.
Vernalis Group Plc
Active Indication-
Inactive Indication
Anxiety Disorders
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
CEB-1128
Target-
Mechanism-
Active Org.-
Originator Org.
Vernalis Group Plc
Active Indication-
Inactive Indication
Anxiety Disorders
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
CEB-1604
Target
NMDA receptor
Mechanism
NMDA receptor antagonists
Active Org.-
Originator Org.
Vernalis Group Plc
Active Indication-
Inactive Indication
Nervous System Diseases
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Vernalis Group Plc
Login to view more data
0 Patents (Medical) associated with Vernalis Group Plc
Login to view more data
1
Literatures (Medical) associated with Vernalis Group Plc
01 Dec 2000IDrugs : the investigational drugs journal
Medicinal chemistry--16th international symposium. 18-22 September 2000, Bologna, Italy.
100 Deals associated with Vernalis Group Plc
Login to view more data
100 Translational Medicine associated with Vernalis Group Plc
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
5
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
CEB-1604
 ( NMDA receptor )		Nervous System Diseases
More
Discontinued
CEB-1128
Anxiety Disorders
More
Discontinued
CEB-1370
Brain Ischemia
More
Discontinued
CEB-1342
Anxiety Disorders
More
Discontinued
VML-275
Melanoma
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free